Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation
| Autor: | W. L. J. Van Putten, G. C. Van Rhoon, Arendjan Wijnmaalen, J. van der Zee, P.A. Helle, B. van der Holt, P. J. M. Rietveld |
|---|---|
| Přispěvatelé: | Radiotherapy, Hematology |
| Rok vydání: | 1999 |
| Předmět: |
Hyperthermia
Adult Cancer Research medicine.medical_specialty Palliative care palliation medicine.medical_treatment Breast Neoplasms Adenocarcinoma local tumour control Disease-Free Survival law.invention Breast cancer breast cancer Randomized controlled trial SDG 3 - Good Health and Well-being law Recurrence medicine Combined Modality Therapy reirradiation Humans Aged business.industry Palliative Care Cancer Regular Article Hyperthermia Induced Middle Aged medicine.disease hyperthermia Surgery Radiation therapy Clinical trial Treatment Outcome Oncology Female Radiotherapy Adjuvant Radiology business |
| Zdroj: | British Journal of Cancer, 79(3/4), 483-490. Nature Publishing Group British Journal of Cancer |
| ISSN: | 0007-0920 |
| Popis: | Both experimental and clinical research have shown that hyperthermia (HT) gives valuable additional effects when applied in combination with radiotherapy (RT). The purpose of this study was evaluation of results in patients with recurrent breast cancer, treated at the Daniel den Hoed Cancer Center (DHCC) with reirradiation (re-RT; eight fractions of 4 Gy twice weekly) combined with HT. All 134 patients for whom such treatment was planned were included in the analysis. The complete response rate in 119 patients with macroscopic tumour was 71%. Including the 15 patients with microscopic disease, the local control rate was 73%. The median duration of local control was 32 months, and toxicity was acceptable. The complete response (CR) rate was higher, and the toxicity was less with the later developed 433-MHz HT technique compared with the 2450-MHz technique used initially. With this relatively well-tolerated treatment, palliation by local tumour control of a worthwhile duration is achieved in the majority of patients. The technique used for hyperthermia appeared to influence the achieved results. The value of HT in addition to this re-RT schedule has been confirmed by a prospective randomized trial in a similar patient group. In The Netherlands, this combined treatment is offered as standard to patients with breast cancer recurring in previously irradiated areas. © 1999 Cancer Research Campaign |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|